Announcement from the University of Pennsylvania for a clinical trial for hemangiosarcoma:
Further Evaluation of the Benefits of a Traditional Chinese Medicine Supplement for Dogs with Splenic Hemangiosarcoma
In this new trial, we will be comparing I’m-Yunity’s® effect on survival time and quality of life to the standard chemotherapy treatment.
Dogs will randomly be chosen to receive either chemotherapy, I’m-Yunity® treatment, or both concurrently, and owners will not know to which treatment group their dog was assigned. Dogs enrolled in this study will have 11 weekly visits, followed by monthly follow-up visits until the end of their life.
- Diagnosis of hemangiosarcoma following splenectomy.
- At least 4 kg.
- Not currently undergoing treatment for cancer.
- No other significant health concerns that are an immediate threat to life.
- Ability to administer oral medication (pills) to your dog.
Please contact the VCIC at 215-573-0302 or firstname.lastname@example.org for more information about this study.